financetom
Business
financetom
/
Business
/
SLB expects flat quarterly revenue, profit amid weaker activity in Saudi Arabia, Latin America
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SLB expects flat quarterly revenue, profit amid weaker activity in Saudi Arabia, Latin America
Jun 24, 2025 9:08 AM

June 24 (Reuters) -

Oilfield services company SLB expects second-quarter

revenue and core profit to be about the same as the previous

quarter due to weaker drilling activity in Saudi Arabia and

Latin America, CEO Olivier Le Peuch said on Tuesday.

The CEO, speaking at the J.P. Morgan Energy, Power &

Renewables Conference in New York, said activity in Saudi had

declined more than expected, with several rigs demobilized and

operations paused at the Jafurah unconventional gas field.

Short-cycle work in Latin America was also down,

contributing to a less favorable geographic activity mix,

impacting margins, the company said.

Oil prices

fell about 5%

to a two-week low on Tuesday on expectations the ceasefire

between Israel and Iran will reduce the risk of oil supply

disruptions in the Middle East.

"Barring any impact to activity in the Persian Gulf from the

conflict, we still expect second-quarter revenue to be flattish

sequentially," Le Peuch said.

SLB's plan to return at least $4 billion to shareholders in

2025 remains unchanged.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
May 26, 2025
In April, Medicus Pharma Ltd. ( MDCX ) agreed to acquire all of Antev’s issued and outstanding shares on a share exchange. Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to an enlarged prostate. Medicus...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BHP Group, Codelco Reach Exploration Agreement for 'Anillo' Property in Chile
BHP Group, Codelco Reach Exploration Agreement for 'Anillo' Property in Chile
May 26, 2025
02:22 PM EDT, 05/12/2025 (MT Newswires) -- BHP Group ( BHP ) and Codelco said Monday they have reached an exploration agreement for the state-owned company's holdings in the Antofagasta Region of Chile. The deal grants BHP the right to explore the 24,000-hectare Anillo property at its own cost. Under the terms, BHP may invest up to $40 million in...
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
May 26, 2025
Apogee Therapeutics, Inc. ( APGE ) on Monday revealed interim data from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with mild-to-moderate asthma. The Phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in 22 adult patients with mild-to-moderate asthma. The trial also evaluated fractional exhaled nitric oxide concentration (FeNO),...
Copyright 2023-2026 - www.financetom.com All Rights Reserved